PreclinicalResearch compound

Pramiracetam

Potent cholinergic racetam, HACU enhancement + AMPA modulation.

Telegram

WHAT IS PRAMIRACETAM?

Detailed overview

Pramiracetam is a high-potency Piracetam analog whose primary action is facilitation of hippocampal high-affinity choline uptake (HACU) – showing a 30-37% increase in ACh turnover in vivo, with a bell-shaped dose-response curve (lower doses often work better). It does NOT modulate GABA, dopamine, noradrenaline, or serotonin – a pure cholinergic profile. Orally well-bioavailable (~4-5 h half-life). Chronic corticosteroid elevation (stress) can block its memory-enhancing effect (PMID 1410129). The typical dose (300-600 mg) is far lower than Piracetam`s. It was prescription-only in Italy as Pramistar; currently withdrawn in several markets.

Mechanism

HACU + AMPA

Half-life

4-6 h

Legal status

EU Rx (IT, withdrawn)

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Headache, often due to choline depletion (well mitigated by a choline source such as alpha-GPC or CDP-choline)
  • Irritability and tension (the most frequently reported side effect)
  • Brain fog and mental dullness, typically with inadequate choline
  • Tiredness and fatigue
  • Tolerance development with prolonged, uninterrupted use
  • Nervousness or mild restlessness, especially at higher doses

Contraindications · 5

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Severe renal or hepatic impairment: caution, as clearance may be affected
  • Concurrent cholinergic drugs (e.g. cholinesterase inhibitors): cholinergic effects may be additive
  • Inadequate choline intake: increases risk of headache and brain fog, a choline source is advised
  • Chronic stress with elevated corticosteroids: may block the memory-enhancing effect

Related Nootropics

Same therapeutic category

Telegram

Have a question about Pramiracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Telegram
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.